Market Access/ News/ News NICE changes its mind on rare bile duct cancer drug from Incyte Phil Taylor cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology 0 Comment Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share X NICE changes its mind on rare bile duct cancer drug from Incyte https://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/